Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index; 9 of the 52 sources its claims cite were checked for support.

Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review

Open access
Calvarysky, Bronya, Dotan, Idit, Shepshelovich, Daniel, Leader, Avi, Cohen, Talia Diker · 2024 · Drug Safety

Abstract

BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity. Their slowing effect of gastric emptying might change oral drug absorption, potentially affecting pharmacokinetics, particularly in the case of medications with a narrow therapeutic index. PURPOSE: The purpose of this systematic review is to summarize data on drug-drug interactions between GLP1RAs and oral drugs. DATA SOURCES: The PubMed and EMBASE databases were searched up to November, 1st 2023. STUDY SELECTION: We selected pharmacokinetic studies of any injectable GLP1RA given with an oral medication, and product prescribing sheets reporting data without access to the original study. DATA EXTRACTION: Two authors independently extracted the data. DATA SYNTHESIS: of drugs with high solubility and permeability (warfarin, contraceptive pills, acetaminophen), drugs with high solubility and low permeability (angiotensin converting enzyme inhibitors), drugs with low solubility and high permeability (statins) and drugs with low solubility and permeability (digoxin). However, the use of GLP1RAs did not exert clinically significant changes in the AUC or differences in clinically relevant endpoints. LIMITATIONS: The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction). CONCLUSIONS: of drugs co-administered with GLP1RAs are consistent with the known delayed gastric output by the latter. Nevertheless, the overall drug exposure was not considered clinically significant. Dose adjustments are probably not required for simultaneous use of GLP1RAs with oral medications. Still, results should be carefully generalized to cases of background kidney dysfunction or when using drugs with narrow therapeutic index. The study is registered in PROSPERO: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022332339 .

Overview

CoChat Summary

TL;DR

This systematic review found that GLP1 receptor agonists can reduce peak concentrations and delay time to peak of some oral drugs, but they did not produce clinically significant changes in overall exposure (AUC) or clinical endpoints in the studies reviewed. The authors conclude that dose adjustments are generally not needed, though caution is warranted for kidney dysfunction, gastroparesis, and narrow-therapeutic-index drugs.

Key findings

  • The review included 22 reports plus 6 prescribing sheets; among the reports were 15 pharmacokinetic studies, 1 pharmacodynamic study, 1 review with unpublished PK data, 3 conference abstracts, 1 case report, and 1 case series.
  • Across drug classes, GLP1RAs often caused reduced Cmax and delayed tmax, but no clinically significant changes in AUC or clinically relevant endpoints were found overall.
  • For warfarin, most AUC and Cmax confidence intervals stayed within 0.8–1.25; exceptions included 19% and 22% reductions in warfarin Cmax with lixisenatide and dulaglutide, respectively, but these were not considered clinically important.
  • For atorvastatin, dulaglutide reduced AUC to 0.786 (90% CI 0.752–0.821), and albiglutide also reduced AUC, but these changes were interpreted as non-clinically significant; in a phase 3 analysis of 966 subjects, statin lipid-lowering effects were comparable to placebo.

Methods

  • Systematic review conducted according to PRISMA; PubMed and EMBASE were searched up to November 1, 2023, with reference-list checking and screening of GLP1RA prescribing sheets.
  • Included human pharmacokinetic studies of any injectable GLP1RA coadministered with an oral medication; studies of GLP1RA interactions with antihyperglycemic medications were excluded.
  • Two authors independently extracted data; outcomes were Cmax, tmax, AUC, and selected pharmacodynamic measures such as INR, lipid levels, gonadotropins, and progesterone; studies were organized using the Biopharmaceutics Classification System (BCS).

Limitations

  • The paper states that the major limitations were enrollment of healthy subjects and insufficient data in conditions affecting pharmacokinetics, such as kidney dysfunction.
  • The discussion adds that many studies used single-dose GLP1RA administration and many coadministered drugs were also given as single doses, so applicability to chronic use is uncertain.
  • Evidence is thin for some clinically important populations and drugs: the text explicitly notes concern about patients with gastroparesis, kidney dysfunction, and narrow therapeutic index drugs; these are limitations evident from the review’s own discussion.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40264-023-01392-3

Cites

44 of 45 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources. From: Page et al. [10]. 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/
Fig. 1 PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources. From: Page et al. [10]. 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/CC BY-NC · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 20 Not checked · 21 Own results and interpretations

22 more claims

Create a free account to see all 49 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 46 references

Research works printed but not linked: 3

  1. Dahmen R, Steinstraesser A, Poitiers F, Ozoux ML, Pinquier JL. Interaction of subcutaneous lixisenatide 20 lg QD on pharmacokinetic and pharmacodynamic properties of oral ramipril 5 MG QD in. Basic Clin Pharmacol Toxicol. 2011;109:89.
  2. Liu YH, Ruus P, Steinstraesser A, Teichert L. Effect of the GLP-1 agonist lixisenatide on the pharmacokinetics of warfarin. In: Abstract conference: 70th scientific sessions of the American Diabetes Association. 2010.
  3. Tham LS, Schneck KB, Geiser JS, Posada M, Dickinson G. Integration of population exposure-response and physiological based pharmacokinetics modeling approaches to evaluate gastric-emptying induced drug interaction risks for dulaglutide. J Pharmacokinet Pharmacodyn. 2018;45:S53–4.

Cited by

See all 97

Metadata

Authors
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Tel Aviv University (IL)
Venue
Drug Safety
Published
2024-01-25
Volume
47
Issue
5
Pages
439-451
ISSN
  • 0114-5916 (ISSN-L)
  • 1179-1942
OpenAlex
W4391218339
Cited by
97
References
46
Citations by year
2026: 58 · 2025: 29 · 2024: 9
FWCI
5.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Drug Safety (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
Tel Aviv University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, drug-drug interactions, oral drug absorption, gastric emptying, pharmacokinetics, drug solubility and permeability, warfarin, oral contraceptives, paracetamol, ACE inhibitors, statins, digoxin, narrow therapeutic index, diabetes mellitus, obesity
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Digoxin, Drug Interactions, Humans, Warfarin, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. https://app.cochat.ai/papers/10.1007/s40264-023-01392-3
The paper
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024). Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety. https://doi.org/10.1007/s40264-023-01392-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.